CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Carcinoembryonic Antigen (CEA) testing coverage criteria

This policy governs coverage and medical necessity of Carcinoembryonic Antigen (CEA) laboratory testing for BCBSRI Medicare Advantage and Commercial products, including required diagnoses and allowed clinical uses for monitoring certain malignancies.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyCarcinoembryonic Antigen (CEA) testing coverage criteria

Policy CodePolicy N/A

Change TypeNo material change

Effective DateJul 1, 2025

Next Review DateMay 3, 2025

Key ActionOrder CEA testing only when filed with a covered diagnosis and ensure only the ordering physician handles authorization and appeals.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

1procedure code listed as medically necessary

2-3mo x ≥2ypost-op CEA testing frequency

07/01/2025effective date

03/05/2025last reviewed

Coverage Criteria

Medically Necessary Indications

Covered when the following conditions are met:

Primary coverage conditions: CEA testing is covered when filed with a covered diagnosis for Medicare Advantage Plans and Commercial Products.

See ICD-10 diagnosis list for CPT 82378 attachment.

Clinical indications: Used for follow-up and monitoring of colorectal carcinoma at treatment decision-making points; alternative marker for certain adenocarcinomas of the lung, small cell carcinoma of the lung, and some gastrointestinal carcinomas when more specific markers are not expressed; measurement at start of treatment and with subsequent cycles for metastatic solid tumors that express CEA.

Preoperative CEA may help determine adequacy of resection.

Frequency guidance: For post-operative surveillance in patients with initial stage II or III colorectal carcinoma, ASCO recommends measuring CEA every 2-3 months for at least two years if resection of liver metastasis would be considered.every 2-3 months x >=2 years

All indications for Carcinoembryonic Antigen (CEA) testing must be filed with a covered diagnosis to be considered for coverage. CEA testing is covered when filed with a covered diagnosis for Medicare Advantage Plans and Commercial Products; benefits and specific coverage may vary by contract and the member’s Benefit Booklet governs.

All other uses of CEA testing — i.e., indications not associated with a covered diagnosis — are not covered for Medicare Advantage and not medically necessary for Commercial Products when there is no evidence of improved net health outcome.

CEA testing performed for indications other than those associated with a covered diagnosis is considered not medically necessary for Commercial Products and is not covered for Medicare Advantage when not filed with a covered diagnosis.

Covered Indications

Follow-up/Monitoring Indications for CEA

Filed with a covered diagnosis; useful at treatment decision-making points and for metastatic disease monitoring.

Filing requirement: CEA testing must be filed with a covered ICD-10 diagnosis to be considered medically necessary.

See coding attachment for ICD-10 list for CPT 82378.

Clinical uses: Follow-up and monitoring of colorectal carcinoma; alternative marker for certain lung and gastrointestinal carcinomas when more specific markers are not expressed; measurement to assess response in metastatic solid tumors that express CEA.

Useful at treatment decision-making points and for metastatic disease monitoring.

Post-operative surveillance (stage II/III colorectal cancer): ASCO recommends post-operative CEA testing every 2-3 months for at least two years in patients with initial stage II or III disease when resection of liver metastasis would be considered.every 2-3 months x >=2 years

Apply when monitoring for recurrence after curative-intent surgery.

Coding

Covered CPT CodesCPTCovered

82378

Carcinoembryonic antigen (CEA)

Post-operative CEA surveillance frequency — ASCO guidance

Recommended surveillance intervalEvery 2–3 months for at least 2 years

Applicable populationPost‑operative patients with initial stage II or III colorectal carcinoma

Clinical triggerWhen resection of liver metastasis would be considered

Guideline sourceASCO recommendation as cited in policy background

Provider Actions

Prior Authorization

Prior authorization is not applicable for Carcinoembryonic Antigen (CEA) testing under this policy.

Step Therapy

No step therapy requirements are specified for CEA testing in this policy.

Note

Filing and Authorization Responsibility

CEA testing must be filed with a covered diagnosis. Benefits and coverage may vary by group and contract — refer to the member's Benefit Booklet, Evidence of Coverage, or Subscriber Agreement for applicable laboratory testing benefits or determinations of not medically necessary/not covered.

Denial Risk

Laboratory Participation in Authorization

Laboratories are prohibited from obtaining prior authorization or participating in the authorization or appeals process on behalf of the ordering physician. Only the ordering physician may engage in authorization, appeals, or other administrative actions related to prior authorization/medical necessity. If a laboratory or third party supports any portion of the authorization process or provides an unauthorized laboratory service, BCBSRI may deny the service, hold the participating laboratory financially liable, and take disciplinary action up to termination from the BCBSRI provider network.

Ordering Requirements

Documentation Required

Ordering physician must handle authorization and appeals; laboratories prohibited from obtaining authorization

Only the ordering physician may be involved in authorization, appeal, or other administrative processes; laboratories may not obtain authorization or participate on behalf of the ordering physician.

Do not delegate authorization or appeals to laboratory representatives or third parties.
Ensure the ordering physician completes any required authorization or appeal submissions.

Background

Carcinoembryonic Antigen (CEA) is a tumor-associated glycoprotein used as a biochemical marker to monitor response to therapy in certain malignancies, particularly colorectal carcinoma. It can be useful preoperatively to assess adequacy of resection and postoperatively at treatment decision points, and for monitoring metastatic disease. Professional guidance (ASCO) recommends post-operative surveillance measurement every 2–3 months for at least 2 years in selected patients (e.g., stage II/III colorectal cancer when resection of liver metastasis would be considered).